10-Q: CG Oncology Reports Q2 2026 Results, Faces Rising Costs

CG Oncology, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026, detailing increased operating expenses and net losses, alongside substantial cash reserves and ongoing clinical development for its bladder cancer treatment.

Summary

• CG Oncology reported a net loss of $79.1 million for the three months ended June 30, 2026, compared to $41.4 million in the same period last year.
• Total revenues for the quarter were $1.16 million, primarily from commercial and development activities, a significant increase from zero in the prior year period due to the Biovire acquisition.
• Research and development expenses rose to $54.7 million from $31.3 million, driven by increased clinical trial costs and personnel expenses.
• General and administrative expenses also increased to $29.0 million from $17.4 million, largely due to higher compensation costs.
• The company ended the quarter with $1.03 billion in cash, cash equivalents, and marketable securities, providing a runway of at least twelve months.
• The company expects to submit a Biologics License Application (BLA) to the FDA in the fourth quarter of 2026 for cretostimogene.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses and increasing operating expenses, despite positive clinical trial data and substantial cash reserves.

Positives

• Substantial cash reserves of $1.03 billion as of June 30, 2026, providing at least a twelve-month operational runway.
• Positive clinical trial data for cretostimogene, including a 75.5% complete response rate in high-risk BCG-unresponsive NMIBC with CIS.
• FDA Fast Track and Breakthrough Therapy designations for cretostimogene.
• Acquisition of Biovire, Inc. in July 2025, providing in-house manufacturing capabilities for cretostimogene.
• Completion of enrollment in the PIVOT-006 Phase 3 trial for intermediate-risk NMIBC.
• The company expects to submit a BLA for cretostimogene in Q4 2026.

Negatives

• Significant increase in net loss to $79.1 million for the quarter ended June 30, 2026, from $41.4 million in the prior year.
• Substantial increase in R&D expenses to $54.7 million from $31.3 million, and G&A expenses to $29.0 million from $17.4 million.
• Accumulated deficit of $518.2 million as of June 30, 2026.
• The company has not generated any revenue from product sales and does not expect to in the foreseeable future.
• The company will require substantial additional funding to continue operations and development.

Risks

• The company has a limited operating history and its revenue and income potential are unproven.
• The company has experienced net losses and negative cash flows from operations since its inception and expects to continue to do so.
• The company's ability to continue as a going concern is dependent on its ability to secure additional funding.
• The development of cretostimogene is subject to numerous risks and uncertainties, including regulatory approval and market acceptance.
• The company relies on third parties for the manufacture of cretostimogene, although it now has Biovire for fill and finish.
• The company may be unable to raise additional capital on favorable terms, or at all, which could delay or terminate development efforts.
• The ongoing legal proceedings with ANI Pharmaceuticals, Inc., although currently in favor of CG Oncology, could still lead to appeals.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances cretostimogene development and seeks regulatory approval. It anticipates submitting a BLA to the FDA in Q4 2026. Future funding will likely come from equity offerings, debt financings, or collaborations, as product sales revenue is not expected in the near future.

Management Comments

• The company has a relatively limited operating history, and the revenue and income potential of the Company's business and market are unproven.
• The Company has experienced net losses and negative cash flows from operations since its inception and, as of June 30, 2026, the Company had an accumulated deficit of $518.2 million.
• We believe, based on our current operating plan, that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations for at least the next twelve months from the date of this Quarterly Report.
• We will not generate revenue from product sales of cretostimogene or any future product candidates unless and until we successfully complete clinical development and obtain regulatory approval, which we expect will take a number of years and may never occur.
• We will need substantial additional funding to support our continuing operations and pursue our growth strategy.

Industry Context

StockSavvy.ai notes that CG Oncology operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically focusing on oncology. The company's progress with cretostimogene, an oncolytic immunotherapy for bladder cancer, aligns with industry trends towards targeted therapies and novel treatment mechanisms. However, the significant increase in R&D and G&A expenses, coupled with substantial net losses, is typical for companies at this clinical stage but highlights the inherent risks and the need for continuous funding.

Comparison to Industry Standards

• Companies in the late-stage clinical development phase, like CG Oncology, typically incur substantial R&D expenses. For instance, similar-stage oncology companies often report R&D expenditures in the tens to hundreds of millions of dollars per quarter.
• The net loss reported is consistent with companies that have not yet achieved commercialization. For example, companies like Moderna (MRNA) or BioNTech (BNTX) in their earlier development phases also reported significant net losses.
• The cash burn rate of approximately $103.4 million for the six months ended June 30, 2026, is substantial but not unusual for a company advancing Phase 3 trials and preparing for regulatory submissions. This necessitates large cash reserves or continuous access to capital markets.
• The focus on bladder cancer, a significant unmet medical need, is a strategic area of interest for many pharmaceutical companies, including those developing immunotherapies and targeted agents.

Legal Proceedings

• ANI Pharmaceuticals, Inc. filed a complaint seeking royalties and damages for alleged unjust enrichment related to an assignment and technology transfer agreement.
• The Superior Court granted CG Oncology's motion for summary judgment regarding royalty payments but denied it for the unjust enrichment claim.
• A jury found in favor of CG Oncology, rejecting ANI's claims for unjust enrichment damages.
• The Superior Court denied ANI's post-trial motions for a new trial and judgment as a matter of law.
• CG Oncology will continue to defend against any appeals brought by ANI.

Related Party Transactions

• In February 2025, SafeGuard Healthcare, LLC (a wholly owned subsidiary) purchased a $26.8 million convertible note from SP Healthcare SPV I, LLC.
• The SPV used these proceeds to acquire assets of Biovire, Inc., a contract manufacturer for cretostimogene.
• In July 2025, SafeGuard converted the note, giving CG Oncology control of SPV and Biovire.
• Biovire was a vendor to CG Oncology prior to the acquisition and continues to provide clinical supply of cretostimogene.

Stakeholder Impact

• Shareholders: Increased net losses and operating expenses may concern investors, but substantial cash reserves and positive clinical data offer potential upside. Dilution risk exists from potential future equity raises.
• Employees: Increased R&D and G&A expenses suggest continued investment in personnel and operations, potentially leading to job growth.
• Creditors: The company has minimal long-term debt ($3 million), and its substantial cash reserves suggest it can meet its obligations.
• Suppliers: The acquisition of Biovire may alter supply chain dynamics for cretostimogene manufacturing, potentially consolidating some aspects internally.

Next Steps

• Complete the Biologics License Application (BLA) submission for cretostimogene to the FDA in the fourth quarter of 2026.
• Continue ongoing clinical trials, including BOND-003, PIVOT-006, and CORE-008.
• Manage and potentially expand manufacturing capabilities through Biovire.
• Continue to seek additional funding to support operations and development.

Key Dates

Recommendation

CG Oncology presents a mixed picture. The substantial cash reserves and promising clinical data for cretostimogene are significant positives. However, the rapidly increasing net losses and operating expenses, coupled with the lack of product revenue and the need for future capital raises, introduce considerable risk. The company is still in a pre-revenue stage with significant development hurdles ahead. A 'hold' recommendation reflects the balance between the potential upside from successful drug development and the inherent risks and financial demands of the biopharmaceutical industry at this stage.

Keywords

bladder cancer, cretostimogene, oncolytic immunotherapy, clinical trials, NMIBC, biopharmaceutical, oncology, BLA submission